Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

NCT ID: NCT04294511

Last Updated: 2020-03-04

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-26
• Study Completion Date: 2023-09-16

Brief Summary

This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Detailed Description

In this study, eligible subject will be enrolled into study arm to accept study treatment. Treatment cycles of chemotherapy will be at most 9 cycles which will be decided by investigators. The percentage of the patient with tumor cell necrosis rate >90% determined by the Independent Review Committee (IRC) will be the primary outcome measures.

Conditions

Osteosarcoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental

camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate

Group Type: EXPERIMENTAL

Camrelizumab in Combination With Neoadjuvant Chemotherapy

Intervention Type: DRUG

camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate

Interventions

Camrelizumab in Combination With Neoadjuvant Chemotherapy

camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate

Intervention Type: DRUG

Other Intervention Names

PD-1 inhibitor

Eligibility Criteria

Inclusion Criteria

1. Age 14 to 65 year old

2. Eastern Cooperative Oncology Group performance status 0-1

3. Histopathologically diagnosed osteosarcomas (except for paraspesarcomas ), have been evaluated in patients have achieved normative resection with neoadjuvant chemotherapy

4. Having measurable lesion according to RECIST 1.1

5. Life expectancy >3 months

6. Patients must have adequate organ function

7. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study

8. Voluntary informed consent , joining the study with good compliance

Exclusion Criteria

1. pregnant or lactating women

2. Known history of hypersensitivity to any components of the camrelizumab formulation, or other antibody formulation.

3. Active central nervous system (CNS) metastases with clinical symptoms , including cerebral edema, steroid requirement, or progressive disease.

4. Patients with other malignant tumor within 5 years , except cured skin basal cell carcinoma, cervical carcinoma and Papillary carcinoma of thyroid.

5. Clinically significant cardiovascular diseases

6. Patients have had prior treatment with PD-1/PD-L1 or CTLA-4 antagonists.Received any study drug within 4 weeks prior to the first study drug administration. Enroll in another clinical study, unless it is an observational (non-interventional) clinical study or an intervention follow-up study. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses > 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration. Note: corticosteroids used for the allergy and nausea, vomiting are allowed. Inhaled or topical use of steroids and adrenocorticosteroid replacement in doses greater than 10mg/ day is permitted in the absence of active autoimmune disease.Patients who have received a live vaccine within 30 days prior to the first study drug administration.Major surgery or major trauma within 4 weeks of first study drug administration. Left ventricular ejection fraction (LVEF) is more than 60% .

(7)Severe infection occurred within 4 weeks before the first first study drug administration (CTC AE > grade 2) (8)Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded. Stable dose of insulin for type 1 diabetes.

(9)History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or organ transplantation and bone marrow transplantation.

(10)Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, pulmonary function damaged seriously etc.

(11)History of active pulmonary tuberculosis infection, or with a history of active pulmonary tuberculosis infection within 1 year prior to enrollment, or with a history of active pulmonary tuberculosis infection prior to 1 year but without formal treatment.

(12)Active hepatitis (transaminase does not meet the inclusion, hepatitis B virus (HBV) DNA ≥10⁴ /ml or hepatitis C virus (HCV) RNA≥103 /ml or higher); Chronic hepatitis B virus carriers who HBV DNA<2000 IU/ml(<104/ml), must receive anti-viral treatment throughout the study.

(13)Known history of psychotropic substance abuse, alcohol abuse and drug abuse.

(14)The investigators did not think the participants were suitable for inclusion.

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Jin Wang,MD

Director of bone and soft tissue

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Cancer Center of Sun-Yat Sen University (CCSYSU)

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jin WANG, MD

Role: CONTACT

wangjinr@sysucc.org.cn

020-87343910

Facility Contacts

Jin Wang, MD

Role: primary

wangjinr@sysucc.org.cn

020-87343910

Other Identifiers

OBU-STS-II-002

Identifier Type: -

Identifier Source: org_study_id